Someone Asked Mark Cuban About Cancer Research Being Canceled; His Surprising Answer: 'Trump Is Doing What You Do After Acquiring A Company'

When President Donald Trump's administration abruptly paused external communications, hiring, travel and grant-review panels at the National Institutes of Health (NIH), the scientific community sounded the alarm. 

Cancer research – which relies heavily on NIH funding – was suddenly uncertain, sparking fears of job losses, delayed clinical trials and interruptions to groundbreaking research. However, billionaire and entrepreneur Mark Cuban saw things differently.

Don't Miss:

• Inspired by Uber and Airbnb – Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets – with $1,000 you can invest at just $0.26/share!
• It’s no wonder Jeff Bezos holds over $70 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started.

On Bluesky, Cuban likened Trump’s action to what occurs following a business acquisition. "Trump is doing what you do after you acquire a company," Cuban wrote. "Crazy, I know. But reality. The Dir of NIH should reach out to DOGE and offer to bring them in to remove inefficiencies. There are always some, and the Director knows what they are. DOGE gets a win. NIH gets back to work."

Cancer Research on Hold

The NIH, which has a $47.4 billion annual budget, allocates over $3 billion to cancer research through the National Cancer Institute (NCI). This funding supports groundbreaking studies, clinical trials and even university and biotech startups working on innovative treatments and diagnostics. As Forbes reports, it has led to significant advancements, such as the HPV vaccine, which has reduced cervical cancer deaths by 65% since its FDA approval in 2006, and rituximab, a breakthrough antibody therapy for cancer.

Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000

But now, funding decisions are frozen because grant review panels have been canceled. Without these panels deciding which projects receive funding, labs may run out of funds, researchers may lose their employment and programs may end. Clinical trials for new treatments are also being delayed, which could be life-threatening for patients waiting on experimental medicines.

Princeton neuroscientist Sam Wang was blunt on Bluesky, writing, "I cannot stress enough the damage this will do to people and U.S. supremacy in research." The consequences could go beyond short-term setbacks, endangering the 34% decrease in cancer death rates since 1991.

See Also: Built on the trusted network of Fortune 500 companies, this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.

Cuban's Pragmatic Approach

Cuban's suggestion to involve DOGE reveals his business-first mindset. He believes inefficiencies within the NIH can be identified and addressed to get the agency back on track. However, for researchers and patients, the stakes go far beyond operational efficiency.

Cancer research isn't a “company” that can be put on pause; it's essential work that directly impacts people's health and future. Although Cuban’s business viewpoint provides one interpretation of the NIH freeze, many scientists believe it to be a threat to advancement and creativity that may have long-term effects on public health.

Read Next:

• Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!
• According to Juniper Research, the total value of B2B cross-border payments stored on the blockchain is projected to exceed $4.4 trillion — Join the first company to bring blockchain payments to Salesforce early with just $100.